We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias.
- Authors
Marchioni, Camila; Santos-Lobato, Bruno Lopes; Queiroz, Maria Eugênia Costa; Crippa, José Alexandre S.; Tumas, Vitor
- Abstract
Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) are frequent complications, and the endocannabinoid system has a role on its pathophysiology. To test the hypothesis that the functioning of the endocannabinoid system would be altered in PD and in LID by measuring plasma and CSF levels of α-N-arachidonoylethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG) in patients with PD with and without LID and in healthy controls. Blood and CSF samples were collected from 20 healthy controls, 23 patients with PD without LID, and 24 patients with PD with LID. The levels of AEA and 2-AG were measured using a highly sensitive column switching ultrahigh-performance liquid chromatography–tandem mass spectrometry method. When pooled together, patients with PD had lower plasma and CSF levels of 2-AG and higher CSF levels of AEA compared to healthy controls (Mann–Whitney statistics = 303.0, p = 0.02). Patients with PD without LID had lower CSF levels of 2-AG (Kruskal–Wallis statistics = 7.76, p = 0.02) and higher CSF levels of AEA levels than healthy controls (Kruskal–Wallis statistics = 8.81, p = 0.01). The findings suggest that the endocannabinoid system participates in the pathophysiology of PD symptoms, but its role in the pathophysiology of LID is still unclear.
- Subjects
PARKINSON'S disease; LIQUID chromatography-mass spectrometry; U-statistics
- Publication
Journal of Neural Transmission, 2020, Vol 127, Issue 10, p1359
- ISSN
0300-9564
- Publication type
Article
- DOI
10.1007/s00702-020-02240-9